<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="italic;} Influenza Other Respir VirusesInfluenza Other Respir Viruses10.1111/(ISSN)1750-2659IRVInfluenza and Other" exact="Respiratory" post="Viruses1750-26401750-2659John Wiley and Sons Inc.Hoboken pmcid: 7182600 doi: 10.1111/irv.12713IRV12713"/>
 <result pre="of Tokyo TokyoJapan[2], Clinic Bambini TokyoJapan[3], Members of the Tokyo" exact="Pediatric" post="Association Public Health Committee TokyoJapan[4], Hagiwara Clinic TokyoJapan[5], Akebonocho"/>
 <result pre="TokyoJapan[5], Akebonocho Clinic TokyoJapan[6], Alpaca Kids Ent Clinic TokyoJapan[7], Wada" exact="Pediatric" post="Clinic TokyoJapan[8], Division of Infectious DiseasesAdvanced Clinical Research CenterInstitute"/>
 <result pre="Kids Ent Clinic TokyoJapan[7], Wada Pediatric Clinic TokyoJapan[8], Division of" exact="Infectious" post="DiseasesAdvanced Clinical Research CenterInstitute of Medical ScienceUniversity of Tokyo"/>
 <result pre="Research CenterInstitute of Medical ScienceUniversity of Tokyo TokyoJapan[9], Department of" exact="Infectious" post="Diseases and Applied ImmunologyIMSUT Hospital of the Institute of"/>
 <result pre="CenterInstitute of Medical ScienceUniversity of Tokyo TokyoJapan[9], Department of Infectious" exact="Diseases" post="and Applied ImmunologyIMSUT Hospital of the Institute of Medical"/>
 <result pre="of Wisconsin MadisonWIUSA[12], Department of Special PathogensInternational Research Center for" exact="Infectious" post="DiseasesInstitute of Medical ScienceUniversity of Tokyo TokyoJapan *Correspondence Yoshihiro"/>
 <result pre="Japan during the 2017�?2018 and 2018�?2019 influenza seasons. Methods A" exact="total" post="of 68 IBVs (61 B/Yamagata/16/88�?like [B/Yamagata]�?lineage and 7 B/Victoria/2/87�?like"/>
 <result pre="G407S mutation in its NA showed a marked reduction in" exact="susceptibility to" post="zanamivir, peramivir, and laninamivir. Conclusions These results highlight the"/>
 <result pre="antigenicity hemagglutinin influenza B virus Japan neuraminidase inhibitors Funding Leading" exact="Advanced" post="Projects for medical innovation (LEAP) from the Japan Agency"/>
 <result pre="(MEXT) of Japan16H0642916H0643416K21723 Japan Initiative for Global Research Network on" exact="Infectious" post="Diseases (J�?GRID) from AMEDJP19fm0108006 NIAID�?funded Center for Research on"/>
 <result pre="of Japan16H0642916H0643416K21723 Japan Initiative for Global Research Network on Infectious" exact="Diseases" post="(J�?GRID) from AMEDJP19fm0108006 NIAID�?funded Center for Research on Influenza"/>
 <result pre="Research on Influenza PathogenesisHHSN272201400008C Research Program on Emerging and Re�?emerging" exact="Infectious" post="Diseases from AMEDJP19fk0108031JP19fk0108056JP19fk0108066 fig-count: table-count: page-count: word-count: Kato�?MiyashitaS, Sakai�?TagawaY,"/>
 <result pre="on Influenza PathogenesisHHSN272201400008C Research Program on Emerging and Re�?emerging Infectious" exact="Diseases" post="from AMEDJP19fk0108031JP19fk0108056JP19fk0108066 fig-count: table-count: page-count: word-count: Kato�?MiyashitaS, Sakai�?TagawaY, YamashitaM,"/>
 <result pre="article is available at https://publons.com/publon/10.1111/irv.12713 1 INTRODUCTION Influenza is an" exact="acute" post="respiratory infectious disease caused by influenza A and B"/>
 <result pre="is available at https://publons.com/publon/10.1111/irv.12713 1 INTRODUCTION Influenza is an acute" exact="respiratory" post="infectious disease caused by influenza A and B viruses."/>
 <result pre="available at https://publons.com/publon/10.1111/irv.12713 1 INTRODUCTION Influenza is an acute respiratory" exact="infectious disease" post="caused by influenza A and B viruses. Currently, two"/>
 <result pre="at https://publons.com/publon/10.1111/irv.12713 1 INTRODUCTION Influenza is an acute respiratory infectious" exact="disease" post="caused by influenza A and B viruses. Currently, two"/>
 <result pre="elicits the production of neutralizing antibodies by the host after" exact="infection" post="or vaccination. The accumulation of point mutations in the"/>
 <result pre="enables viruses to evade host immune responses induced by prior" exact="infections" post="or vaccinations, resulting in the emergence of new antigenic"/>
 <result pre="influenza; however, mutations in the NA active site reduce its" exact="susceptibility to" post="NA inhibitor drugs, leading to the emergence of drug�?resistant"/>
 <result pre="2018�?2019 season, even though influenza B viruses circulated at a" exact="lower" post="level in this season compared with the previous season."/>
 <result pre="AND METHODS 2.1 Clinical specimens After informed consent was obtained," exact="respiratory" post="specimens were collected from patients with influenza�?like symptoms who"/>
 <result pre="until cytopathic effects were evident. Cell culture supernatants were harvested," exact="viral" post="RNA was extracted and subjected to RT�?PCR, and the"/>
 <result pre="viral RNA was extracted and subjected to RT�?PCR, and the" exact="viral" post="genes were sequenced (see below). Influenza B viruses were"/>
 <result pre="In brief, plasmids encoding the complementary DNAs for the eight" exact="viral" post="RNA segments under the control of the human RNA"/>
 <result pre="as PolI plasmids), and plasmids for the expression of the" exact="viral" post="PB2, PB1, PA, and nucleoprotein proteins derived from influenza"/>
 <result pre="virus propagation. All virus stocks were sequenced to confirm the" exact="absence of" post="unwanted mutations. 2.5 Real�?time RT�?PCR Real�?time PCR was performed"/>
 <result pre="is provided in Table S1. 2.6 RT�?PCR and sequencing of" exact="viral" post="genes Viral RNA was extracted from infected cell culture"/>
 <result pre="in Table S1. 2.6 RT�?PCR and sequencing of viral genes" exact="Viral" post="RNA was extracted from infected cell culture supernatant by"/>
 <result pre="extracted from infected cell culture supernatant by using the QIAmp" exact="Viral" post="RNA Mini Kit (Qiagen) and reverse�?transcribed to cDNA by"/>
 <result pre="reverse�?transcribed to cDNA by using Superscript III reverse transcriptase (Thermo" exact="Fisher" post="Scientific) and the Uni9/FluB1 primer.12 PCR was performed with"/>
 <result pre="by using BigDye Terminator version 3.1 Cycle Sequencing Kits (Thermo" exact="Fisher" post="Scientific), and were then analyzed on an ABI Prism"/>
 <result pre="then analyzed on an ABI Prism 3130xl Genetic Analyzer (Thermo" exact="Fisher" post="Scientific). A list of the primers and probes used"/>
 <result pre="with 1000 bootstrap replicates using mega version 7.0.26.13 2.8 Experimental" exact="infection" post="of ferrets Six�? to seven�?month�?old female ferrets (Wuxi Sangosho"/>
 <result pre="version 7.0.26.13 2.8 Experimental infection of ferrets Six�? to seven�?month�?old" exact="female" post="ferrets (Wuxi Sangosho Biotechnology Co., Ltd.) were used in"/>
 <result pre="and 2018�?2019 seasons During the 2017�?2018 and 2018�?2019 seasons, a" exact="total" post="of 554 respiratory specimens were collected from patients with"/>
 <result pre="During the 2017�?2018 and 2018�?2019 seasons, a total of 554" exact="respiratory" post="specimens were collected from patients with an influenza�?like illness"/>
 <result pre="B/Victoria�?lineage. These results are consistent with the National Institute of" exact="Infectious" post="Diseases (NIID) report that influenza B viruses of the"/>
 <result pre="These results are consistent with the National Institute of Infectious" exact="Diseases" post="(NIID) report that influenza B viruses of the B/Yamagata�?"/>
 <result pre="those of other viruses from the Global Initiative on Sharing" exact="Avian" post="Influenza Data (GISAID) EpiFlu database. Since the 2015�?2016 season,"/>
 <result pre="to the vaccine virus B/Florida/4/2006, with titers 16�? or 32�?fold" exact="lower" post="than the homologous titer. These results indicate that all"/>
 <result pre="cell culture�?propagated vaccine strain B/Texas/02/2013, with titers eightfold or 16�?fold" exact="lower" post="than the homologous titer of this antiserum (Tables 2"/>
 <result pre="by the antiserum against B/Colorado/06/2017 with titers fourfold or eightfold" exact="lower" post="than the homologous titer of this antiserum. These results"/>
 <result pre="laninamivir (Table 4). The isolate showed a marked reduction in" exact="susceptibility to" post="peramivir, zanamivir, and laninamivir (64�?, 167�?, and 204�?fold increases"/>
 <result pre="NA genes from B/Phuket/3073/2013). This isolate also exhibited moderately reduced" exact="susceptibility to" post="oseltamivir carboxylate (eightfold). Table 4 Virus sensitivity to NA"/>
 <result pre="carrying the G407S mutation in their NA, which confers reduced" exact="susceptibility to" post="NA inhibitors, were sporadically detected in Japan during the"/>
 <result pre="virus (B/Tokyo/UT�?AC032/2018) was isolated from a specimen collected from an" exact="adult" post="patient (a 41�?year�?old female) prior to drug treatment. Although"/>
 <result pre="influenza B viruses. This virological surveillance study may have been" exact="limited" post="by the fact that samples were collected in a"/>
 <result pre="limited by the fact that samples were collected in a" exact="limited" post="area in Japan and by the relatively small number"/>
 <result pre="data file. ACKNOWLEDGEMENTS We thank the Global Initiative on Sharing" exact="Avian" post="Influenza Data (GISAID) for sharing the influenza virus sequence"/>
 <result pre="generating antisera in ferrets. This research was supported by Leading" exact="Advanced" post="Projects for medical innovation (LEAP) from the Japan Agency"/>
 <result pre="16H06434), by the Japan Initiative for Global Research Network on" exact="Infectious" post="Diseases (J�?GRID) from AMED (JP19fm0108006), by a Research Program"/>
 <result pre="by the Japan Initiative for Global Research Network on Infectious" exact="Diseases" post="(J�?GRID) from AMED (JP19fm0108006), by a Research Program on"/>
 <result pre="AMED (JP19fm0108006), by a Research Program on Emerging and Re�?emerging" exact="Infectious" post="Diseases from AMED (JP19fk0108031, JP19fk0108056, and JP19fk0108066), and by"/>
 <result pre="(JP19fm0108006), by a Research Program on Emerging and Re�?emerging Infectious" exact="Diseases" post="from AMED (JP19fk0108031, JP19fk0108056, and JP19fk0108066), and by the"/>
 <result pre="2IulianoAD, RoguskiKM, ChangHH, et al. Estimates of global seasonal influenza�?associated" exact="respiratory" post="mortality: a modelling study. Lancet. 2018;391:1285�?1300.29248255 3HayAJ, GregoryV, DouglasAR,"/>
 <result pre="resistance. Influenza Other Respi Viruses. 2013;7:25�?36. 7collab: National Institute of" exact="Infectious" post="Diseases in Japan . Infectious Agents Surveillance Report. https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data95j.pdf."/>
 <result pre="Influenza Other Respi Viruses. 2013;7:25�?36. 7collab: National Institute of Infectious" exact="Diseases" post="in Japan . Infectious Agents Surveillance Report. https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data95j.pdf. Accessed"/>
 <result pre="2013;7:25�?36. 7collab: National Institute of Infectious Diseases in Japan ." exact="Infectious" post="Agents Surveillance Report. https://nesid4g.mhlw.go.jp/Byogentai/Pdf/data95j.pdf. Accessed 27 May 2019. 8HatakeyamaS,"/>
 <result pre="with a novel eukaryotic vector (Recombinant DNA; B�?actin promoter; bovine" exact="papilloma" post="virus; transfection; interleukin�?2; G418 selection; copy number). Gene. 1991;108:193�?199.1660837"/>
</results>
